Samplytics Technologies Pvt. Ltd., 44, SKS Plaza, 2nd Floor, 100 Ft Road, Koramangala 4th Block, Bangalore, 452012, India.
Inito Inc., 355 Bryant Street, Unit 403, San Francisco, CA, 94107, USA.
Sci Rep. 2023 Jun 7;13(1):9227. doi: 10.1038/s41598-023-36539-w.
Home use tests to monitor hormone trends during the menstrual cycle have been available over-the-counter for a long time. However, these tests often depend upon manual readouts and hence may lead to false analysis. Furthermore, a lot of these tests are also not quantitative. The aim of this study was to evaluate the accuracy of the quantitative home-based fertility monitor, Inito Fertility Monitor (IFM) and to use it to identify novel hormone trends in natural menstrual cycles. There were two aspects to our analysis: (i) Evaluating the efficacy of Inito Fertility Monitor in the measurement of urinary Estrone-3-glucuronide (E3G), Pregnanediol glucuronide (PdG) and Luteinizing hormone (LH), and (ii) A retrospective study of patients' hormone profiles using IFM. To evaluate the efficacy, the recovery percentage of the three hormones from IFM was evaluated using standard spiked solutions, the accuracy of measurement was calculated and the correlation between reproducible values from IFM and ELISA was established. During the validation of IFM, novel hormone trends were also observed. In order to reinforce the observations, a second group of 52 women was recruited. Assessment of the accuracy of IFM and evaluation of the volunteer urine samples was performed in a laboratory. Home assessment of hormone analysis was carried out using IFM. For the validation study, 100 women aged 21-45 years with cycle lengths ranging from 21 to 42 days were recruited. The participants had no previously diagnosed infertility conditions and their cycle lengths did not vary for more than 3 days from the expected cycle length. Daily first morning urine samples were collected from these 100 women. For the second group, 52 women were selected meeting the same criteria set for the validation study and IFM was provided to these women for testing at home. Coefficient of variation and recovery percentage of IFM with respect to laboratory based ELISA. Percentage occurrence of novel hormone trends and AUC analysis of a novel criteria identified for confirming ovulation. We observed that with all three hormones, IFM had an accurate recovery percentage. We found that the assay has an average CV of 5.05% in PdG measurement, 4.95% in E3G measurement and 5.57% in LH measurement. Furthermore, in predicting the concentration of E3G, PdG and LH in urine samples, we show that IFM has a high correlation with ELISA. In this study, we could also reproduce hormones trends across the menstrual cycle that have been observed by previous studies. We also identified a novel criterion for earlier confirmation of ovulation which could accurately distinguish ovulatory from anovulatory cycles with 100% specificity and had an area under the ROC curve of 0.98. In addition, we identified a new hormone trend which could be observed in 94.5% of the ovulatory cycles. The Inito Fertility Monitor is an effective tool for calculating the urinary concentrations of E3G, PdG and LH and can also be used to provide accurate fertility scores and confirm ovulation. We show that certain hormone trends associated with urinary E3G, PdG and LH could be accurately captured using IFM. In addition, we report a novel criterion for earlier confirmation of ovulation compared to existing criteria. Finally, we present a novel hormone pattern associated with most of the menstrual cycles by examining hormone profiles from the volunteers recruited for the clinical trial.Trial registration: The trial is registered at the current controlled trials ISRCTN registry #ISRCTN15534557.
家庭使用的激素检测试剂盒可以自行检测月经周期内的激素变化,此类产品很早就已经在市面上有售。然而,这些测试通常依赖于手动读取,因此可能会导致错误的分析。此外,这些测试中的很多都不是定量的。本研究旨在评估定量家用生育监测仪 Inito Fertility Monitor (IFM) 的准确性,并使用它来识别自然月经周期中的新激素趋势。我们的分析有两个方面:(i) 评估 IFM 在测量尿雌酮-3-葡糖苷酸 (E3G)、孕烷二醇葡糖苷酸 (PdG) 和黄体生成素 (LH) 方面的效果,(ii) 使用 IFM 对患者的激素谱进行回顾性研究。为了评估效果,使用标准加标溶液评估了三种激素从 IFM 中的恢复百分比,计算了测量的准确性,并建立了 IFM 与 ELISA 之间可重复值的相关性。在 IFM 的验证过程中,也观察到了新的激素趋势。为了加强观察,我们招募了第二组 52 名女性。在实验室中对 IFM 的准确性进行评估,并对志愿者尿液样本进行评估。使用 IFM 进行激素分析的家庭评估。在验证研究中,我们招募了 100 名年龄在 21-45 岁之间、周期长度为 21-42 天的女性。参与者没有被诊断为不孕的既往病史,她们的周期长度与预期周期长度相差不超过 3 天。我们从这 100 名女性中每天收集第一次晨尿样本。对于第二组,我们选择了符合验证研究设定标准的 52 名女性,并为这些女性提供 IFM 进行家庭测试。IFM 相对于实验室 ELISA 的变异系数和恢复百分比。确定新的确认排卵的标准的新激素趋势的出现百分比和 AUC 分析。我们观察到,对于所有三种激素,IFM 的恢复百分比都很准确。我们发现该检测在 PdG 测量中的平均 CV 为 5.05%,在 E3G 测量中的平均 CV 为 4.95%,在 LH 测量中的平均 CV 为 5.57%。此外,在预测尿液样本中 E3G、PdG 和 LH 的浓度时,我们表明 IFM 与 ELISA 具有高度相关性。在这项研究中,我们还可以重现之前研究中观察到的整个月经周期的激素趋势。我们还确定了一个新的排卵确认标准,该标准可以 100%特异性地准确区分排卵和无排卵周期,ROC 曲线下面积为 0.98。此外,我们还发现了一种新的激素趋势,在 94.5%的排卵周期中都可以观察到。Inito Fertility Monitor 是一种计算尿 E3G、PdG 和 LH 浓度的有效工具,也可用于提供准确的生育评分并确认排卵。我们表明,某些与尿 E3G、PdG 和 LH 相关的激素趋势可以使用 IFM 准确捕捉。此外,与现有标准相比,我们报告了一种更早确认排卵的新标准。最后,通过检查从参加临床试验的志愿者那里获得的激素谱,我们提出了一种与大多数月经周期相关的新激素模式。试验注册:该试验在当前对照试验 ISRCTN 注册处注册,注册号为 ISRCTN84623614。